免费的行情软件APP网站九幺,欧美成A人片在线观看久,亚洲精品无码久久久久久久,欧美老妇大p毛茸茸

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線：400-901-9800  客服QQ：4009019800  技術答疑  技術支持  質量反饋  人才招聘  關于我們  聯系我們
強姦亂倫中文字幕在線觀看,高大丰满肥熟妇丰满大白屁股,www亚洲精品少妇裸乳一区二区
首頁 > 產品中心 > 一抗 > 產品信息
Rabbit Anti-Phospho-PPAR Gamma (ser273)  antibody (bs-4888R)  
~~~促銷代碼KT202411~~~
訂購熱線：400-901-9800
訂購郵箱：sales@1mylove.com
訂購QQ：  400-901-9800
技術支持：techsupport@1mylove.com
說明書： 50ul  100ul  200ul
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
大包裝/詢價

產品編號 bs-4888R
英文名稱 Rabbit Anti-Phospho-PPAR Gamma (ser273)  antibody
中文名稱 磷酸化過氧化酶活化增生受體γ抗體
別    名 Phospho-PPAR Gamma(ser273); P-PPAR Gamma (Phospho-ser273); GLM1; CIMT1; NR1C3; PPARG; PPARG1; PPARG2; PPARG5; PPARgamma; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator-activated receptor gamma; PPAR gamma; PPAR-gamma; PPARG_HUMAN; PPAR-γ; PPAR γ; PPARγ;   
Specific References  (40)     |     bs-4888R has been referenced in 40 publications.
[IF=38.104] Zhang Yudian. et al. 3-Hydroxybutyrate ameliorates insulin resistance by inhibiting PPARγ Ser273 phosphorylation in type 2 diabetic mice. SIGNAL TRANSDUCT TAR. 2023 May;8(1):1-10  WB ;  Mouse.  
[IF=12.067] Yang, Nanfei. et al. Blockage of PPARγ T166 phosphorylation enhances the inducibility of beige adipocytes and improves metabolic dysfunctions. CELL DEATH DIFFER. 2022 Nov;:1-13  WB ;  Mouse.  
[IF=7.658] Lei Ma. et al. Identification of the anti-fungal drug fenticonazole nitrate as a novel PPARγ-modulating ligand with good therapeutic index: Structure-based screening and biological validation. Pharmacol Res. 2021 Nov;173:105860  WB ;  Mouse.  
[IF=7.422] Dan Wu. et al. A Novel Peroxisome Proliferator-Activated Receptor Gamma Ligand Improves Insulin Sensitivity and Promotes Browning of White Adipose Tissue in Obese Mice. Mol Metab. 2021 Oct;:101363  WB ;  Mouse.  
[IF=7.419] Fangyuan Chen. et al. Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation. BIOMED PHARMACOTHER. 2022 Oct;154:113653  WB ;  Mouse.  
[IF=7.199] Zhang C et al. Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPARγ-CD36 Pathway. Diabetes. 2019 Jul 10. pii: db181055.  WB ;  Mouse.  
[IF=7.103] Hou et al. CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss. (2018) Genes.Dis. 5:290-299  WB ;  Mouse.  
[IF=6.133] Huan Y et al. A novel specific PPARγ modulator YR4‐42 ameliorates hyperglycemia and dyslipidemia and hepatic steatosis in diet‐induced obese mice. Diabetes Obes Metab. 2019 Jul 31.  WB ;  Mouse.  
[IF=6.064] Maiara Ferreira Terra. et al. Obesity-Linked PPARγ Ser273 Phosphorylation Promotes Beneficial Effects on the Liver, despite Reduced Insulin Sensitivity in Mice. BIOMOLECULES. 2023 Apr;13(4):632  WB ;  Mouse.  
[IF=5.58] Agrawal, S., et al. "Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome." Scientific Reports 6 (2016): 24392.  IHC-P ;  Rat.  
[IF=5.486] Jian Yu. et al. Selective PPARγ modulator Diosmin improves insulin sensitivity and promotes browning of white fat. J BIOL CHEM. 2023 Feb;:103059  IP ;  Mouse.  
[IF=5.458] Claire Bryant. et al. Selective Modulator of Nuclear Receptor PPARγ with Reduced Adipogenic Potential Ameliorates Experimental Nephrotic Syndrome. Iscience. 2022 Feb;:104001  WB ;  Rat.  
[IF=5.307] Junyuan Tang. et al. Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPARγ-modulating ligand. BIOORG CHEM. 2022 Oct;:106191  WB ;  Mouse.  
[IF=5.195] Yu Wang. et al. An integrated study of Shenling Baizhu San against hyperuricemia: Efficacy evaluation, core target identification and active component discovery. J ETHNOPHARMACOL. 2022 Sep;295:115450  WB ;  Quail.  
[IF=5.116] Pengyu Hong. et al. Therapeutic potential of small extracellular vesicles derived from lipoma tissue in adipose tissue regeneration—an in vitro and in vivo study. Stem Cell Res Ther. 2021 Dec;12(1):1-13  IHC ;  Human.  
[IF=5.08] Liu, Chang, et al. "Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis." Scientific Reports 5 (2015).  WB ;  Mouse.  
[IF=5.059] Stephanie Kimet al. Triphenyl phosphate is a selective PPARγ modulator that does not induce brite adipogenesis in vitro and in vivo. Arch Toxicol . 2020 Sep;94(9):3087-3103.  WB ;  mouse.  
[IF=4.966] Ye Zhanget al. Thymopentin improves the survival of septic mice by promoting the production of 15‐deoxy‐prostaglandin J2 and activating the PPARγ signaling pathway. FASEB J . 2020 Sep;34(9):11772-11785.  WB ;  mouse.  
[IF=4.5] Liu, Lei, et al. "Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down‐regulation of phosphorylation of PPARγ in 3T3‐L1 cells." Journal of Cellular and Molecular Medicine (2017).  WB ;  Mouse.  
[IF=4.26] Alla, Joshua Abd, et al. "Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice." Journal of Biological Chemistry 291.6 (2016): 2583-2600.  WB ;  Mouse.  
[IF=4.26] Maganti, Aarthi V., et al. "Peroxisome Proliferator-Activated Receptor-γ Activation Augments the β Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-Obese Diabetic Mice."Journal of Biological Chemistry (2016): jbc-M116.  WB ;  Mouse.  
[IF=4.26] Stechschulte, Lance A., et al. "Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ and RUNX2." Journal of Biological Chemistry (2016).  WB ;  Mouse.  
[IF=4.171] Yingying Tian. et al. Exogenous natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance via activation of PPARα/γ in mice. Food Funct. 2020 Sep;11(9):8248-8258  WB ;  Mouse.  
[IF=3.86] Liu, Lei, et al. "Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats." Molecular and Cellular Endocrinology (2016).  WB ;  Rat.  
[IF=3.73] Kolli, Vipula, et al. "Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass." PLOS ONE 9.5 (2014): e96323.  WB ;  Mouse.  
[IF=3.698] Yaru Guo. et al. Pioglitazone Attenuates Ischemic Stroke Aggravation By Blocking PPARγ Reduction and Inhibiting Chronic Inflammation in Diabetic Mice. EUR J NEUROSCI. 2022 Aug;:  WB ;  Mouse.  
[IF=3.514] Li B et al. Resistin up-regulates LPL expression through the PPARγ-dependent PI3K/AKT signaling pathway impacting lipid accumulation in RAW264. 7 macrophages.Cytokine. 2019 Jul;119:168-174.  WB ;  Mouse.  
[IF=3.461] Yukiko Yamashita. et al. Discovery of FXR/PPARγ Dual Partial Agonist. BIOORGAN MED CHEM. 2023 Mar;:117238  WB ;  Mouse.  
[IF=3.386] Choung S et al. Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice.PPAR Res. 2018 Jun 13;2018:4292509.  WB ;  Mouse.  
[IF=3.23] Sarr, Ousseynou, et al. "Low birth weight male guinea pig offspring display increased visceral adiposity in early adulthood." PloS one 9.6 (2014): e98433.  WB ;  Guinea Pig.  
產品類型 磷酸化抗體 
研究領域 腫瘤  細胞生物  信號轉導  細胞凋亡  激酶和磷酸酶  表觀遺傳學  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應 Human,Rabbit (predicted: Mouse,Rat,Pig,Sheep,Cow,Chicken)
產品應用 WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 57kDa
細胞定位 細胞核 細胞漿 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthesised phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser273: DK(p-S)PF 
亞    型 IgG
純化方法 affinity purified by Protein A
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產品介紹 This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

Function:
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.

Subunit:
Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with DNTTIP2, MAP2K1/MEK1, PRMT2 and TGFB1I1. Interacts with PDPK1. Interacts with ASXL1 AND ASXL2.

Subcellular Location:
Nucleus. Cytoplasm.

Tissue Specificity:
Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

DISEASE:
Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.

Similarity:
Belongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

SWISS:
P37231

Gene ID:
5468

Database links:

Entrez Gene: 5468?Human

Entrez Gene: 19016?Mouse

Entrez Gene: 25664?Rat

SwissProt: P37231?Human

SwissProt: P37238?Mouse

SwissProt: O88275?Rat

Unigene: 162646?Human

Unigene: 3020?Mouse

Unigene: 23443?Rat



產品圖片
Sample: Lane 1: Human A549 cell lysates Lane 2: Human 293T cell lysates Lane 3: Human HepG2 cell lysates Primary: Anti-Phospho-PPAR Gamma (ser273) (bs-4888R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 57 kDa Observed band size: 57 kDa
Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-Phospho-PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated(bs-4888R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: human gastric carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-Phospho-PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated(bs-4888R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: A549 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (Phospho-PPAR Gamma (ser273)) polyclonal Antibody, Unconjugated (bs-4888R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
phosphopeptide non phosphopeptide
版權所有 2004-2026 www.1mylove.com 北京博奧森生物技術有限公司
通過國際質量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫療器械-質量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網安備110107000727號